These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3066962)

  • 1. [Problems of a pharmacologic search for inhibitors of platelet aggregation].
    Lakin KM
    Kardiologiia; 1988 Oct; 28(10):120-6. PubMed ID: 3066962
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacological action on the thromboxane and prostacyclin balance in the body].
    Lakin KM; Makarov VA; Novikova NV; Tret'iak VM; Rukazenkov IuE
    Farmakol Toksikol; 1984; 47(2):67-79. PubMed ID: 6425078
    [No Abstract]   [Full Text] [Related]  

  • 3. [Thrombocyte aggregation inhibitors. A new class of active substances].
    Böhm R; Giessler AJ
    Pharmazie; 1986 Jan; 41(1):1-7. PubMed ID: 3515372
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibitory effect of the Korean herbal medicine, Dae-Jo-Whan, on platelet-activating factor-induced platelet aggregation.
    Chang GT; Kang SK; Kim JH; Chung KH; Chang YC; Kim CH
    J Ethnopharmacol; 2005 Dec; 102(3):430-9. PubMed ID: 16125889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New drugs for the inhibition of the pro-thrombotic effects of prostaglandins and thromboxane A2].
    Patscheke H
    Verh Dtsch Ges Inn Med; 1990; 96():696-702. PubMed ID: 2092508
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet Dysfunction in Type 1 Diabetes: Stressing the Thromboxanes.
    Wisinski JA; Kimple ME
    Diabetes; 2016 Feb; 65(2):349-51. PubMed ID: 26798121
    [No Abstract]   [Full Text] [Related]  

  • 7. Stimulation of vascular PGI2 by organic nitrates and its significance for the antianginal effect.
    Schrör K; Ahland B; Darius H; Weiss P
    Scand J Clin Lab Invest Suppl; 1984; 173():33-40. PubMed ID: 6442000
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of low-dose aspirin on platelet aggregation and the biosynthesis of PGI2 and TXA2 in patients with coronary heart disease].
    Gao SW; Chen ZJ; Tao SQ
    Zhonghua Nei Ke Za Zhi; 1987 Apr; 26(4):209-12, 255. PubMed ID: 3308356
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
    Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
    Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipyridamole and platelet function.
    Lancet; 1978 Dec; 2(8102):1257-9. PubMed ID: 82767
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platelet aggregation and PAF-acether. Pharmacologic interference].
    Vargaftig BB; Fouque F; Lefort J
    J Pharmacol; 1984; 15 Suppl 1():69-84. PubMed ID: 6374298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments of TXA2 antagonists.
    Hamanaka N
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():663-5. PubMed ID: 2526556
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development.
    Patrono C; Patrignani P; Rocca B; Landolfi R
    Thromb Haemost; 1995 Jul; 74(1):396-400. PubMed ID: 8578493
    [No Abstract]   [Full Text] [Related]  

  • 15. [In vitro study of the mechanism of the platelet anti-aggregant action of picotamide (G 137)].
    Berrettini M; De Cunto M; Romanelli A; Volpato I; Orzalesi G; Nenci GG
    Boll Soc Ital Biol Sper; 1983 Mar; 59(3):309-15. PubMed ID: 9704127
    [No Abstract]   [Full Text] [Related]  

  • 16. [Thromboxane A2 antagonist, prostacyclin (PGI2)--its in vivo secretion and action mechanism].
    Okuma M
    Nihon Rinsho; 1978 Dec; 36(12):3830-5. PubMed ID: 372621
    [No Abstract]   [Full Text] [Related]  

  • 17. Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects.
    Hirsh J; Salzman EW; Harker L; Fuster V; Dalen JE; Cairns JA; Collins R
    Chest; 1989 Feb; 95(2 Suppl):12S-18S. PubMed ID: 2644095
    [No Abstract]   [Full Text] [Related]  

  • 18. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice.
    Kashiwagi H; Yuhki K; Kojima F; Kumei S; Takahata O; Sakai Y; Narumiya S; Ushikubi F
    J Pharmacol Exp Ther; 2015 May; 353(2):269-78. PubMed ID: 25740898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of antiaggregants in kidney diseases].
    Lapchyns'ka II; Dudar IO
    Lik Sprava; 1993; (10-12):14-20. PubMed ID: 8030297
    [No Abstract]   [Full Text] [Related]  

  • 20. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.
    Humphrey PP; Hallet P; Hornby EJ; Wallis CJ; Collington EW; Lumley P
    Circulation; 1990 Jan; 81(1 Suppl):I42-52; discussion I59-60. PubMed ID: 2136817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.